(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Video of clashes over purported conscription orders misrepresented as anti-war protest in Israel - 2Moscow: Russia well-positioned to withstand oil market shocks
- 3The most effective method to Pick the Ideal Shrewd Bed for Your Special Rest Needs
- 4Top Music and Dance Celebration: Which One Gets You Going?
- 5Sahel coups push Africa to top of global democratic declines, report finds
- Why screening for the deadliest cancer in the U.S. misses most cases
- Investigating Inside Plan and Home Style: Change Your Residing Space
- Instructions to Warmly greet Certainty and Appeal
- The Most Important Crossroads in Olympic History
- Israel reports killing another senior Iranian oil official
- The most exciting exoplanet discoveries of 2025
- German politician urges more face-to-face interaction in digital age
- Israel says it killed armed Hamas 'terrorists' in Gaza
- Manual for Financial plan Agreeable PC
